Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
Adamas Pharmaceuticals
Adamas Pharmaceuticals
(ADMS)
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
*Currency in USD
Company Revenue
Quarterly
Quarterly
Annual
Annual
Projections
*Quarterly sales USD (in millions)
Mock data
Subscribe for the real data
Revenue by Drug
Marketed Drugs
No data
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Fluzone
respiratory syncytial virus infections
,
paramyxoviridae infections
,
respiratory syncytial viruses
,
h5n1 subtype influenza a virus
,
influenza in birds
,
multiple sclerosis
,
neoplasms
,
virus diseases
,
dengue virus
,
orthomyxoviridae
,
infections
,
communicable diseases
,
infectious myxomatosis
,
h1n1 subtype influenza a virus
,
whooping cough
,
tetanus
,
diphtheria
,
poliomyelitis
,
obesity
,
dengue
,
severe dengue
,
tetany
,
haemophilus infections
,
haemophilus influenzae type b
,
meningococcal infections
,
flavivirus infections
,
yellow fever
,
inactivated vaccines
,
morbid obesity
,
human influenza
,
orthomyxoviridae infections
,
healthy volunteers/patients
,
pneumonia
,
heart failure
,
stroke
,
myocardial infarction
,
infarction
,
multiple myeloma
,
plasma cell neoplasms
,
plasmacytoma
,
chronic obstructive pulmonary disease
,
lung diseases
,
obstructive lung diseases
,
pregnancy
,
immune system diseases
,
pregnancy complications
,
micronutrients
,
toxicological phenomena
,
otitis media
,
bronchiolitis
,
otitis
,
only child
,
atrial fibrillation
,
cardiovascular diseases
,
coronary disease
,
cardiac arrhythmias
,
heart arrest
,
emergencies
,
diabetes mellitus
,
respiratory tract infections
,
inferior wall myocardial infarction
,
severe acute respiratory syndrome
,
behavior and behavior mechanisms
,
immunization
Flumist
respiratory syncytial virus infections
,
paramyxoviridae infections
,
respiratory syncytial viruses
,
h5n1 subtype influenza a virus
,
influenza in birds
,
multiple sclerosis
,
neoplasms
,
virus diseases
,
dengue virus
,
orthomyxoviridae
,
infections
,
communicable diseases
,
infectious myxomatosis
,
h1n1 subtype influenza a virus
,
whooping cough
,
tetanus
,
diphtheria
,
poliomyelitis
,
obesity
,
dengue
,
severe dengue
,
tetany
,
haemophilus infections
,
haemophilus influenzae type b
,
meningococcal infections
,
flavivirus infections
,
yellow fever
,
inactivated vaccines
,
morbid obesity
,
human influenza
,
orthomyxoviridae infections
,
healthy volunteers/patients
,
pneumonia
,
heart failure
,
stroke
,
myocardial infarction
,
infarction
,
multiple myeloma
,
plasma cell neoplasms
,
plasmacytoma
,
chronic obstructive pulmonary disease
,
lung diseases
,
obstructive lung diseases
,
pregnancy
,
immune system diseases
,
pregnancy complications
,
micronutrients
,
toxicological phenomena
,
otitis media
,
bronchiolitis
,
otitis
,
only child
,
atrial fibrillation
,
cardiovascular diseases
,
coronary disease
,
cardiac arrhythmias
,
heart arrest
,
emergencies
,
diabetes mellitus
,
respiratory tract infections
,
inferior wall myocardial infarction
,
severe acute respiratory syndrome
,
behavior and behavior mechanisms
,
immunization
Flucelvax
respiratory tract infections
Isoxaflutole
healthy volunteers/patients
,
non-small-cell lung carcinoma
,
type 2 diabetes mellitus
,
covid-19
,
virus diseases
,
sickle cell anemia
,
erectile dysfunction
,
systemic lupus erythematosus
,
psoriatic arthritis
,
arthritis
,
prostatic neoplasms
,
breast neoplasms
,
ovarian neoplasms
,
pancreatic neoplasms
,
esophageal neoplasms
,
lung neoplasms
,
urinary bladder neoplasms
,
uterine neoplasms
,
liver neoplasms
,
kidney neoplasms
,
uterine cervical neoplasms
,
colonic neoplasms
,
hematologic diseases
,
hematopoietic stem cell transplantation
,
bone marrow transplantation
,
acromegaly
,
cardiovascular diseases
,
neoplasms
,
rare diseases
,
treatment adherence and compliance
,
oncogenes
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use